Corcept Therapeutics company profile
Company profile
Corcept Therapeutics has 730 employees and is headquartered in Redwood City, United States.
With 730 employees, Corcept Therapeutics develops medicines that modulate cortisol activity for conditions linked to excess cortisol. Its marketed product, Korlym, is prescribed in the United States to control blood sugar in adults with Cushing's syndrome who have type 2 diabetes or impaired glucose tolerance and who either did not respond to surgery or cannot undergo it. The pipeline includes relacorilant for hypercortisolism, miricorilant, which is in a Phase 1b study for metabolic dysfunction-associated steatohepatitis, and several cortisol modulators, among them dazucorilant, for Lou Gehrig's disease.
In the fiscal year ended December 2025, revenue reached USD 761.4 million, up 12.8% from the prior year, and net income came to USD 99.7 million. The company was founded in 1998 and is headquartered in Redwood City, California.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 101 Redwood Shores Parkway, 94065, Redwood City
- Employees
- 730
- Chief executive
- Joseph Belanoff
- Founded
- 1998
- Fiscal year
- January - December
- Listing
- CORT · NASDAQ
- Currency
- USD
- ISIN
- US2183521028
- Website
- corcept.com
Corcept Therapeutics and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Corcept TherapeuticsCORT | United States | $9.36B | 730 | 0.8% | 190.2 |
| Madrigal PharmaceuticalsMDGL | United States | $9.93B | 915 | -10.7% | — |
| BioMarin PharmaceuticalBMRN | United States | $11.09B | 3,221 | 16.3% | 146.8 |
| Summit TherapeuticsSMMT | United States | $11.32B | 265 | 0.0% | — |
| Bio-TechneTECH | United States | $11.43B | 3,000 | 21.7% | 66.8 |
| Twist BioscienceTWST | United States | $7.4B | 979 | -28.8% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
